prothymosin alpha comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Alistair Barkley who goes on the run with Eddie when they are framed for Alistair's murder and the destruction of his laboratory Fred Ward as FBI Agent Leon Ford, who leads the investigation to discover the cause of the destruction of the laboratory; initially focusing on Eddie and Lily, he soon suspects the involvement of government organizations Kevin Dunn as FBI Agent Doyle, Ford's assistant in the investigation who helps Ford track down Eddie, Lily, and later, C-Systems Brian Cox as Lyman Earl Collier, Chairman of C-Systems Research who is behind the conspiracy to keep the hydrogen power plant a secret Joanna Cassidy as Maggie McDermott, an old friend of Eddie's who lives in an observatory in Wisconsin, where Eddie and Lily escape to after a warrant is issued for their arrest Chelcie Ross as FBI Agent Ed Rafferty Nicholas Rudall as Dr. Alistair Barkley, head of the project to develop energy from the water who is later suffocated Tzi Ma as Lu Chen, Project Manager on the Hydrogen Project and Dr. Barkley's right-hand man; when Barkley is killed, Dr. Chen is kidnapped and forced to work at C-Systems Krzysztof Pieczyński as Lucasz Screbneski, the scientist on the original project who is secretly working for C-Systems Eddie Bo Smith Jr. and Danny Goldring as Yusef Reed and Clancy Butler, Collier's right hand men for C-Systems Margaret Travolta as Anita Fermi, Shannon's personal assistant. In addition, Michael Shannon and Neil Flynn make appearances as a van driver and a Wisconsin State Police Trooper, respectively.
DiCaprio's second role in 2010 was in Christopher Nolan's critically acclaimed ensemble science-fiction film Inception. Inspired by the experience of lucid dreaming and dream incubation, the film features Dom Cobb (DiCaprio), an "extractor" who enters the dreams of others to obtain information that is otherwise inaccessible. Cobb is promised a chance to regain his old life in exchange for planting an idea in a corporate target's mind. DiCaprio was fascinated with the idea of a "dream-heist" and the potential for his character to manipulate his dreamworld and impact his real life. Made on a budget of $160 million, the film grossed $836 million worldwide to become DiCaprio's second highest-grossing film. To star in this film, DiCaprio agreed to a pay cut from his $20 million fee and opted for a share in first-dollar gross points, which entitled him to a percentage of the cinema ticket sales. The risk proved fruitful, as DiCaprio earned $50 million from the film, becoming his highest payday yet. DiCaprio starred as J. Edgar Hoover in Clint Eastwood's J. Edgar (2011). A biopic about Hoover, the film focuses on his career as an FBI director, including an examination of his private life as an alleged closeted homosexual. Critics felt that the film lacked coherence overall but commended DiCaprio's performance. Roger Ebert praised DiCaprio's ability to bring depth and nuance to the character, suggesting that his performance conveyed aspects of Hoover's personality that were possibly even unknown to the man himself.
C.; Schwab, M.; Viegas, M. H.; Roseboom, T. J. (2015). "Prenatal Undernutrition and Leukocyte Telomere Length in Late Adulthood". The American Journal of Clinical Nutrition. 102 (3): 655–660. doi:10.3945/ajcn.115.112326. PMID 26178721. S2CID 4493294. Chen, R.; et al. (2012). "Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes". Cell. 148 (6): 1293–1507. doi:10.1016/j.cell.2012.02.009. PMC 3341616. PMID 22424236. Bernardes De Jesus, B.; Schneeberger, K.; Vera, E.; Tejera, A.; Harley, C. B.; Blasco, M. A. (2011). "The Telomerase Activator TA-65". Aging Cell. 10 (4): 604–621. doi:10.1111/j.1474-9726.2011.00700.x. PMC 3627294. PMID 21426483.
Sources: en.wikipedia.org
The pineal gland is located in the diencephalon of the brain. It primarily releases melatonin, which influences daily rhythms and may have an antigonadotropic effect in humans. It may also influence the melanotropes and melanocytes located in the skin.
=== Established lesion === The hallmark of the established lesion is the overwhelming presence of plasma cells in relation to the prior stages of inflammation. Beginning two to three weeks after first plaque formation, the established lesion is widespread in both human and animals populations and can be seen commonly associated with the placement of orthodontic bands on molars. Similar to the initial and early lesions, the established lesion features an inflammatory reaction confined to the area near the base of the gingival sulcus, but unlike prior stages, displays plasma cells clustered around blood vessels and between collagen fibers outside the immediate area of the reaction site. While most of the plasma cells produce IgG, a significant number do produce IgA (and rarely, some produce IgM). The presence of complement and antigen-antibody complexes is evident throughout the connective and epithelial tissue. It is in the established lesion that epithelial proliferation and apical migration begin. In health, the junctional epithelium creates the most coronal attachment of the gum tissue to the tooth at or near the cementoenamel junction. In the established lesion of periodontal disease, the connective tissue lying subjacent to the junctional epithelium is nearly destroyed, failing to properly support the epithelium and buttress it against the tooth surface.
=== Similar species === It can easily be mistaken for a variety of other members of the genus Tricholoma, such as T. auratum, T. aestuans, T. intermedium, T. sejunctum, and T. sulphureum. Other similar species include Floccularia albolanaripes and F. luteovirens.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.